PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Xenothera, Nantes, France.\', \'Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM) 1136, Institut Pierre Louis d\'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Virology, Paris, France.\', \'Hong Kong University (HKU)-Pasteur Research Pole, School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.\', \'Department of Infectious Disease, Nantes University Hospital, Nantes, France.\', \'Institut National de la Santé et de la Recherche Médicale (INSERM) CIC1413, Nantes University Hospital, Nantes, France.\', \'Department of Cell Biology and Infection, Institut Pasteur, Paris, France.\', \'Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.\', \'The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.761250
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34868003
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all